Overexpression and activation of RET are present in the pathogenesis of many human cancers, particularly thyroid, lung and some brain cancers.107,108 In 2019, the FDA approved selpercatinib as the first selective RET-inhibitor for the treatment of thyroid cancer and non-small cell lung carcinoma (NSCLC). This evidence concerns the gene RET and brain cancer.